NCT00510718 - A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

July 23, 2007

Primary Completion Date

December 8, 2008

Study Completion Date

April 2, 2018

Conditions

Prostate CancerHormone Refractory Prostate Cancer

Interventions

DRUG

MDV3100

MDV3100 daily until progression or dose-limiting toxicity

Trial Locations (9)

Memorial Sloan-Kettering Cancer Center, New York

MSKCC- Sidney Kimmel Center, New York

Oregon Health & Science University, Portland

Seattle Cancer Care Alliance, Seattle

University of Washington Medical Center, Seattle

Dana-Farber Cancer Institute (DFCI), Boston

Beth Israel Deaconess Medical Center (BIDMC), Boston

Investigational Pharmacy Services, Houston

The University of Texas M.D. Anderson Cancer Center, Houston